NA
DGX icon

NewEdge Advisors’s Quest Diagnostics DGX Stock Holding History

NewEdge Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65M Buy
12,508
+550
+5% +$108K 0.01% 1073
2026
Q1 		$2.34M Sell
11,958
-1,552
-11% -$302K 0.01% 1026
2025
Q4 		$2.34M Buy
13,510
+298
+2% +$54.3K 0.01% 989
2025
Q3 		$2.52M Buy
13,212
+87
+0.7% +$15.4K 0.01% 900
2025
Q2 		$2.36M Buy
13,125
+3,604
+38% +$626K 0.01% 859
2025
Q1 		$1.61M Buy
9,521
+2,441
+34% +$401K 0.01% 954
2024
Q4 		$1.07M Sell
7,080
-543
-7% -$84.5K 0.01% 1121
2024
Q3 		$1.18M Buy
7,623
+435
+6% +$65K 0.01% 1027
2024
Q2 		$984K Buy
7,188
+757
+12% +$104K 0.01% 1078
2024
Q1 		$856K Sell
6,431
-2,564
-29% -$333K 0.01% 1073
2023
Q4 		$1.23M Buy
8,995
+915
+11% +$120K 0.01% 846
2023
Q3 		$985K Sell
8,080
-1,422
-15% -$189K 0.01% 868
2023
Q2 		$1.34M Buy
9,502
+1,535
+19% +$212K 0.02% 741
2023
Q1 		$1.13M Buy
7,967
+4,189
+111% +$599K 0.01% 740
2022
Q4 		$506K Buy
3,778
+1,209
+47% +$174K 0.01% 777
2022
Q3 		$315K Sell
2,569
-115
-4% -$15.1K 0.01% 1179
2022
Q2 		$357K Buy
+2,684
New +$366K 0.01% 1140
2022
Q1 		– Sell
-7,830
Closed -$1.35M – 1264
2021
Q4 		$1.35M Buy
7,830
+4,204
+116% +$640K 0.02% 592
2021
Q3 		$527K Buy
+3,626
New +$531K 0.01% 732
2020
Q4 		– Sell
-5,032
Closed -$576K – 1006
2020
Q3 		$576K Buy
5,032
+258
+5% +$30.5K 0.02% 531
2020
Q2 		$544K Sell
4,774
-1,184
-20% -$126K 0.02% 515
2020
Q1 		$478K Buy
5,958
+1,371
+30% +$142K 0.02% 464
2019
Q4 		$489K Buy
4,587
+256
+6% +$26.7K 0.02% 535
2019
Q3 		$463K Buy
+4,331
New +$445K 0.02% 518
2017
Q3 		– Sell
-205
Closed -$22.3K – 539
2017
Q2 		$22.3K Buy
+205
New +$21.7K ﹤0.01% 709

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

NewEdge Advisors's DGX Position: Q2 2026 in Review

NewEdge Advisors increased its Quest Diagnostics (DGX) stake by 4.6% in Q2 2026, buying an estimated $108K and bringing the position to 12,508 shares worth $2.65M. The position accounts for 0.01% of the portfolio, ranked #1073.

NewEdge Advisors first reported a position in DGX in Q2 2017 and has held it in 25 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • NewEdge Advisors held 12,508 shares of Quest Diagnostics worth $2.65M as of Q2 2026.
  • NewEdge Advisors bought 550 Quest Diagnostics shares in Q2 2026, an estimated $108K.
  • Quest Diagnostics made up 0.01% of NewEdge Advisors's portfolio in Q2 2026, its #1073 holding.
  • NewEdge Advisors first reported a position in Quest Diagnostics in Q2 2017 and has held it in 25 quarters since.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.